BLA 761488 · Alexion Pharm
Klygefa
Gefurulimab · Injection
NovelOrphanCDER novel approval, Nov 13, 2026: To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Nov 13, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2026 Original approval · Type 1 - New Molecular Entity NovelOrphanLabel
1 products under this application
- KLYGEFA · GEFURULIMAB 600MG · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gefurulimab" as an intervention, any sponsor and status, largest first.
- A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult ParticipantsPivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06208488 · 175 participants · Start Nov 22, 2023 · Primary completion Sep 17, 2024
Drug: Gefurulimab PFS-SD; Gefurulimab AI · For: Healthy Adult Participants
Sites: Toronto, Canada; Laval, Canada
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06677138 · 8 participants · Start Oct 28, 2024 · Primary completion Mar 19, 2025
Drug: gefurulimab · For: Healthy
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.
Gwathmey KG, Saccà F, Howard JF, et al. · JAMA Neurol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.
McEneny A, Cong X, Yee M, et al. · Clin Ther 2026 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.